Alpro Group and AstraZeneca Collaborate to Advance Early Detection Across the Cardio-Kidney-Metabolic Spectrum and Raise Awareness of Hyperkalemia
Nationwide #AreYourKidneysOK+? initiative expands access to subsidised blood screening, public education, and pharmacist support for 12,550 Malaysians. KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 19 August 2026 – As chronic conditions such as diabetes, cardiovascular disease and chronic kidney disease continue to affect Malaysians, early detection is becoming increasingly important in…
In Malaysia, a collaboration between Alpro Group and AstraZeneca Malaysia has been established to advance early detection of Cardio-Kidney-Metabolic (CKM) conditions and raise awareness of hyperkalemia. This nationwide initiative, known as #AreYourKidneysOK+?, focuses on providing subsidised blood screening, public education, and pharmacist support to 12,550 Malaysians.
The campaign highlights the interconnectedness of CKM conditions, where issues in one area can increase risks for other parts of the body, with hyperkalemia being a notable complication that often goes unnoticed until it leads to serious heart complications. By offering subsidised blood tests, the campaign aims to make early detection more accessible and empower Malaysians to take proactive steps toward managing their health.
The initiative also includes a digital health education platform that provides easily understandable information about hyperkalemia, its causes, risk factors, symptoms, and its relationship with chronic kidney disease. Through the Alpro Group's community healthcare network, pharmacists are available to offer personalized guidance and support, ensuring that individuals understand the importance of screening and how to seek appropriate medical assessment.
Written by urgent.news from Arabian Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
